Educational Grant
Helsinn Therapeutics (U.S.) Inc. invites proposals for independent educational programs and materials.
Helsinn may provide funding in the form of an Educational Grant to support legitimate educational programs and activities that are in line with our therapeutic areas of interest. Helsinn is committed to funding programs that communicate the most current disease awareness, scientific, and medical information, to the medical and healthcare community to improve patient care. Educational Grant support will be considered for any scientific, educational or professional program, meeting or event that is organized, controlled, and conducted by an independent third party, including but not limited to, accredited and non-accredited medical education (CME and non-CME) for HCPs and/ or patients, disease awareness, or medical conferences. Educational Grants that are awarded should be multi-supported and must be in accordance with Helsinn’s policies, applicable laws and regulations (federal and state), the PhRMA Code, and ACCME for accredited programs.
Proposals for Educational Grant must include a cover letter that states a description of the proposed educational program, including the subject matter, timing, location, proposed audience, expected number of attendees, and start and end date of each activity (if applicable). Additionally, include with the proposal, the amount requested from Helsinn, indication of multi-support, authorized signature, and complete contact information on whom the funds are to be paid with tax ID number and appropriate attachments (e.g., W-9, proposal, invitations, detailed budget, etc).
Funding requests for multi-supported live presentations, written enduring materials, online courses, and conference symposia from organizations (e.g. hospitals, universities, societies, medical-education vendors) will be reviewed and assessed in conjunction with Helsinn’s goal to help physicians and other healthcare professionals to obtain information and insights that contribute to the improvement of patient care in oncology supportive care and therapeutics. Disease states and areas of interest considered can include, but are not limited to, the following:
Chemotherapy Induced Nausea and Vomiting (CINV)
• Burden of disease, risk factors and clinical consequences
• Updates to antiemesis guidelines
• New advancements in delayed, refractory and/or breakthough CINV in moderately emetogenic chemotherapy and/or highly emetogenic chemotherapy
• Multiday use of CINV therapies
• Case-based presentations with multidisciplinary approach
Mycosis Fungoides Cutaneous T-Cell Lymphoma (MF-CTCL)
• Disease awareness, diagnosis and treatment education for dermatologists, derm-oncs, PAs and others
• New advancements in MF-CTCL
Patient Education (in the Helsinn areas of interest)
Please submit all Educational Grant Proposals to: usgrantrequests@helsinn.com
